drugset / Trial / NCT00293501

Tinzaparin in Treating Patients With Metastatic Kidney Cancer That Cannot Be Removed By Surgery

NCT00293501

Open-labelTreatment

Summary

RATIONALE: Tinzaparin may stop the growth of kidney cancer by blocking blood flow to the tumor. PURPOSE: This phase I/II trial is studying the side effects of tinzaparin and to see how well it works in treating patients with metastatic kidney cancer that cannot be removed by surgery.

Timeline

Start
2005-12
Primary completion
2007-02
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Tinzaparin Other / unclassified Subcutaneous

Indications